DE3667488D1 - Verfahren zur herstellung von glucagon oder dessen derivaten in einem transformierten hefestamm. - Google Patents

Verfahren zur herstellung von glucagon oder dessen derivaten in einem transformierten hefestamm.

Info

Publication number
DE3667488D1
DE3667488D1 DE8686300384T DE3667488T DE3667488D1 DE 3667488 D1 DE3667488 D1 DE 3667488D1 DE 8686300384 T DE8686300384 T DE 8686300384T DE 3667488 T DE3667488 T DE 3667488T DE 3667488 D1 DE3667488 D1 DE 3667488D1
Authority
DE
Germany
Prior art keywords
derivatives
glucagon
transformed yeast
expression
yeast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8686300384T
Other languages
English (en)
Inventor
Kjeld Norris
Lars Thim
Fanny Norris
Mogens Trier Hansen
Alister James Moody
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of DE3667488D1 publication Critical patent/DE3667488D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/30—Signal or leader sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Emergency Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE8686300384T 1985-01-22 1986-01-20 Verfahren zur herstellung von glucagon oder dessen derivaten in einem transformierten hefestamm. Expired - Lifetime DE3667488D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK27885A DK27885A (da) 1985-01-22 1985-01-22 Fremstilling af peptider

Publications (1)

Publication Number Publication Date
DE3667488D1 true DE3667488D1 (de) 1990-01-18

Family

ID=8091749

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8686300384T Expired - Lifetime DE3667488D1 (de) 1985-01-22 1986-01-20 Verfahren zur herstellung von glucagon oder dessen derivaten in einem transformierten hefestamm.

Country Status (17)

Country Link
US (1) US4826763A (de)
EP (1) EP0189998B1 (de)
JP (2) JPH0720435B2 (de)
AT (1) ATE48643T1 (de)
AU (1) AU587218B2 (de)
CA (1) CA1294232C (de)
DE (1) DE3667488D1 (de)
DK (1) DK27885A (de)
ES (1) ES8708250A1 (de)
FI (1) FI87800C (de)
GR (1) GR860149B (de)
IE (1) IE58726B1 (de)
MX (1) MX163776B (de)
NO (1) NO172185C (de)
NZ (1) NZ214883A (de)
PT (1) PT81872B (de)
ZA (1) ZA86393B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5151354A (en) * 1986-08-21 1992-09-29 Cornelius Hollenberg Fermentation processes using amylolytic enzyme producing microorganisms
EP0268772B1 (de) * 1986-09-19 1995-04-26 ZymoGenetics, Inc. Expression des biologisch aktiven Faktors XIII
JPH01187499A (ja) * 1988-01-21 1989-07-26 Science & Tech Agency 原子炉解体用ロボット
IL93173A0 (en) * 1989-02-01 1990-11-05 Shionogi & Co Production of glucagon
US6172039B1 (en) 1990-04-16 2001-01-09 Apex Bioscience, Inc. Expression of recombinant hemoglobin and hemoglobin variants in yeast
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
US5510459A (en) * 1991-01-17 1996-04-23 Zymogenetics, Inc. Glucagon antagonists
US5408037A (en) * 1991-01-17 1995-04-18 Zymogenetics, Inc. Methods for detecting glucagon antagonists
EP0653965B1 (de) * 1992-07-06 1996-05-15 Beckman Instruments, Inc. Flüssigkeitsversorgungssystem mit Mehrwegventil
DK144093D0 (de) * 1993-12-23 1993-12-23 Novo Nordisk As
US5652216A (en) * 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
AU746633B2 (en) * 1997-05-16 2002-05-02 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
WO2004060387A1 (en) * 2002-12-27 2004-07-22 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
MX362028B (es) 2009-02-03 2019-01-04 Amunix Pharmaceuticals Inc Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
ES2705249T3 (es) 2009-06-08 2019-03-22 Amunix Operating Inc Polipéptidos reguladores de glucosa y métodos para su producción y uso
MX366864B (es) 2012-02-27 2019-07-26 Amunix Operating Inc Composiciones de conjugados de xten y métodos para realizarlas.
WO2020074583A1 (en) 2018-10-09 2020-04-16 Fresenius Kabi Ipsum S.R.L. Process for the manufacture of glp-1 analogues
EP3753946A1 (de) 2019-06-18 2020-12-23 Fresenius Kabi iPSUM S.r.l. Verbessertes verfahren zur herstellung von hochreinem glucagon
EP3986919A1 (de) 2019-06-18 2022-04-27 Fresenius Kabi iPSUM S.r.l. Verfahren zur herstellung von glucagon
US20230287040A1 (en) 2019-11-13 2023-09-14 Amunix Pharmaceuticals, Inc. Barcoded xten polypeptides and compositions thereof, and methods for making and using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401759A (en) * 1980-05-01 1983-08-30 Harvey Rubin Detection and isolation of glucagon mRNA using a synthetic oligodeoxynucleotide
DK283180A (da) * 1980-07-01 1982-01-02 Novo Industri As Polypeptider og derivater deraf
US4546082A (en) * 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins

Also Published As

Publication number Publication date
GR860149B (en) 1986-05-21
FI87800C (fi) 1993-02-25
AU587218B2 (en) 1989-08-10
JPH06292594A (ja) 1994-10-21
AU5247286A (en) 1986-07-31
FI860251A0 (fi) 1986-01-20
FI87800B (fi) 1992-11-13
FI860251A (fi) 1986-07-23
NO860178L (no) 1986-07-23
ES551042A0 (es) 1987-10-01
DK27885D0 (da) 1985-01-22
NO172185B (no) 1993-03-08
NZ214883A (en) 1988-04-29
JPS61181398A (ja) 1986-08-14
MX163776B (es) 1992-06-22
IE860162L (en) 1986-07-22
EP0189998B1 (de) 1989-12-13
ES8708250A1 (es) 1987-10-01
IE58726B1 (en) 1993-11-03
JPH0746986B2 (ja) 1995-05-24
US4826763A (en) 1989-05-02
PT81872A (en) 1986-02-01
DK27885A (da) 1986-07-23
ATE48643T1 (de) 1989-12-15
CA1294232C (en) 1992-01-14
PT81872B (pt) 1988-05-27
JPH0720435B2 (ja) 1995-03-08
EP0189998A1 (de) 1986-08-06
NO172185C (no) 1993-06-16
ZA86393B (en) 1987-03-25

Similar Documents

Publication Publication Date Title
DE3667488D1 (de) Verfahren zur herstellung von glucagon oder dessen derivaten in einem transformierten hefestamm.
AU2790292A (en) Viral recombinant vectors for expression in muscle cells
AU573768B2 (en) Hyaluronic acid from streptococci
IT8167406A0 (it) Procedimento e veicolo per la produzione di polipeptidi mediante espressione nei batteri di un codice genetico di struttura
ATE209679T1 (de) Proteine mit faktor viii aktivität, verfahren zu deren herstellung unter verwendung von genetisch modifizierten zellen und diese enthaltende zusammensetzungen
ATE78055T1 (de) Verfahren zur herstellung von proteinen und transformierten zellen und dna-konstruktionen zur korrektur von mankos und wirtszellen sowie deren herstellung und verwendung.
DE68907611D1 (de) Auf teilchen immobilisierte lipasezubereitung, verfahren zur herstellung und deren verwendung.
EP0139878A3 (de) Herstellung von Immun-Interferon und seiner m-RNS
DE3880583D1 (de) Polyurethan-emulsion, deren verwendung zur herstellung von bahnmaterialien sowie herstellungsverfahren dieser materialien.
DE69628566D1 (de) Neurale transplantation durch verwendung von pluripotenten neuroepithelzellen
DE3484926D1 (de) Expressionsplasmide fuer die herstellung eines heterologen proteins in bakterien.
ES2078243T3 (es) Mejoras en o relativas a la expresion eucariotica.
EP0196879A3 (de) Verfahren zur Erzeugung von unbehaarten Schweinen
DE3586940D1 (de) Polypeptid und dessen verfahren zur herstellung.
DE3878410D1 (de) Verfahren zur erhoehung von gen-expression.
ATE116366T1 (de) Verfahren zur herstellung eines menschlichen ''neutrophil chemotactic factor''-polypeptids.
EP0592685A4 (de) Planze resistent gegen mindestens zwei viren und dessen preparation.
EP0422217A4 (en) Human recombinant placental ribonuclease inhibitor and method of production
EP0300425A3 (de) Verfahren zur Herstellung von Proteinen in löslicher Form
ATE50453T1 (de) Spezifisches polypeptid produzierende hybridzellinien, erhaeltlich aus primaerzellen, die spontan faehig sind zur expres sion dieses polypeptids oder eines aehnlichen polypeptids, verfahren zum erhalten dieser hybridzellen und deren verwendung zur herstellung dieses polypeptids.
DE3882247D1 (de) Verfahren zur expressionsregulation eines fremdgens mittels kontrolle der zuckerkonzentration in einem medium und verfahren zur herstellung eines fremdgenproduktes.
DE3853590D1 (de) Rinder granulocyt-makrophagenkolonie stimulierender faktor.
DE3583601D1 (de) Plasmid, verfahren zu dessen herstellung, dieses plasmid enthaltender mikroorganismus und verfahren zur zuechtung des mikroorganismus.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition